Erlotero 150 Mg Erlotinib Tablets
Erlotero 150 Mg Erlotinib Tablets

Erlotero 150 Mg Erlotinib Tablets

MOQ : 100 Boxes

Erlotero 150 Mg Erlotinib Tablets Specification

  • Salt Composition
  • Erlotinib 150 mg
  • Indication
  • Non-Small Cell Lung Cancer, Pancreatic Cancer
  • Dosage Form
  • Tablet
  • Feature
  • Prescription medicine, oral administration
  • Ingredients
  • Erlotinib Hydrochloride
  • Physical Color/Texture
  • Film-coated tablets
  • Storage Instructions
  • Store below 30C, protect from light and moisture
  • Shelf Life
  • 24 months
  • Marketed By
  • Zydus Healthcare
  • ATC Code
  • L01EB02
  • Administration Route
  • Oral
  • Manufactured By
  • Zydus Healthcare Ltd.
  • Regulatory Classification
  • Schedule H Prescription Drug
  • Prescription Required
  • Yes
  • Strength
  • 150 mg
  • Packaging Type
  • Box of 30 tablets (10 x 3 blister strips)
  • Brand Name
  • ERLOTERO-150
 

Erlotero 150 Mg Erlotinib Tablets Trade Information

  • Minimum Order Quantity
  • 100 Boxes
  • Payment Terms
  • Cash in Advance (CID)
  • Supply Ability
  • 5000 Boxes Per Month
  • Delivery Time
  • 2-10 Days
  • Main Domestic Market
  • All India
 

Erlotero 150 Mg Erlotinib Tablets About



Experience the enviable efficacy of ERLOTERO-150, a sought-after anticancer therapy crafted by Zydus Healthcare Ltd. Each box contains 30 film-coated tablets, offering an advanced solution for patients battling non-small cell lung cancer and pancreatic cancer. Easy to redeem with a valid prescription, these tablets are conveniently administered orally. Add to Cart for a superb boost in cancer therapeutics. Strictly regulated under Schedule H, ERLOTERO-150 is a prescription medicine of trusted quality and reliability in oncology care, with a shelf life of 24 months.

Enviable Anti-Cancer Solution with Superb Effectiveness

ERLOTERO-150 Mg Erlotinib Tablets feature film-coated oral tablets designed for targeted cancer therapy, providing significant benefits for patients with non-small cell lung cancer and pancreatic cancer. Manufactured by Zydus Healthcare, this prescription medicine stands out for its reliability and high manufacturing standards, making it a sought-after choice among oncologists. The superb mechanism of action targets specific cancer cell pathways, supporting improved outcomes. Recommended by specialists, ERLOTERO-150 delivers its potent efficacy with confident dependability.


Exceptional Packaging, Certifications, and Easy Supply Offer

ERLOTERO-150 is offered in a robust box of 30 tablets (10 x 3 blister strips), ensuring protection from light and moisture for optimal preservation. With a shelf life of 24 months, every batch meets stringent regulatory standards and comes with official certifications. Take advantage of our quotation system and sample availability for healthcare professionals. Efficient transport services are provided to ensure quick and safe product delivery, making it convenient to redeem and restock this essential medication.


FAQ's of Erlotero 150 Mg Erlotinib Tablets:


Q: How should Erlotero 150 Mg Erlotinib Tablets be administered?

A: Erlotero 150 Mg Erlotinib Tablets are intended for oral administration and should be taken exactly as prescribed by your oncologist or healthcare provider.

Q: What are the primary benefits of using ERLOTERO-150 for cancer treatment?

A: ERLOTERO-150 offers targeted therapy for non-small cell lung cancer and pancreatic cancer, contributing to more effective cancer control with a trusted safety profile.

Q: When is ERLOTERO-150 prescribed and who can use it?

A: This medication is prescribed by oncologists for adults diagnosed with non-small cell lung cancer or pancreatic cancer and is only available with a valid medical prescription.

Q: Where is ERLOTERO-150 manufactured and marketed?

A: ERLOTERO-150 is manufactured by Zydus Healthcare Ltd. and marketed across India, adhering to strict pharmaceutical regulations and standards.

Q: What is the process to redeem ERLOTERO-150 and how can samples be requested?

A: To obtain ERLOTERO-150, present a valid prescription at registered pharmacies or request a quotation for bulk orders. Healthcare professionals may contact authorized suppliers to request samples for institutional evaluation.

Q: How should Erlotero 150 Mg Tablets be stored?

A: Store the tablets below 30C, protected from light and moisture, to maintain their efficacy throughout the 24-month shelf life.

Tell us about your requirement
product

Price:

Quantity
Select Unit

  • 50
  • 100
  • 200
  • 250
  • 500
  • 1000+
Additional detail
Mobile number

Email

More Products in Oncology Drugs Category

Biocon Canmab Trastuzumab 440 Mg Injection

Biocon Canmab Trastuzumab 440 Mg Injection

Minimum Order Quantity : 100 Boxes

Dosage Form : Injection

Application : Other, IV infusion for cancer therapy

Salt Composition : Trastuzumab

Physical Color/Texture : Other , White to pale yellow lyophilized powder

Indication : HER2positive breast and gastric cancer

Bdenza Enzalutamide 40 Mg Capsules

Bdenza Enzalutamide 40 Mg Capsules

Minimum Order Quantity : 10 Boxes

Dosage Form : Capsules

Application : Other, Oral administration, prescription medicine

Salt Composition : Enzalutamide 40 mg

Physical Color/Texture : Other , Capsule form (color may vary depending on manufacturer batch)

Indication : For the treatment of prostate cancer

Abiraterone Acetate Bdron 500mg

Abiraterone Acetate Bdron 500mg

Minimum Order Quantity : 10 Boxes

Dosage Form : Tablets

Application : Other, For Oral Use

Salt Composition : Abiraterone Acetate

Physical Color/Texture : Other , White to offwhite tablets

Indication : Prostate Cancer

Soranib Sorafenib 200 Mg Tablets

Soranib Sorafenib 200 Mg Tablets

Minimum Order Quantity : 10 Boxes

Dosage Form : Tablet

Application : Other, Oral use, prescriptiononly anticancer medication

Salt Composition : Sorafenib 200 mg

Physical Color/Texture : Other , Tablet form, filmcoated, usually light colored

Indication : Used for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid carcinoma (DTC)



Back to top